CVS Quote, Financials, Valuation and Earnings

HCA Healthcare, Inc. has a net margin of -3.88% compared to CVS Health Corp.'s net margin of 9.93%. CVS Health Corp.'s return on equity of 0.57% beat HCA Healthcare, Inc.'s return on equity of 3428.29%.

CVS Health Corp. has a consensus price target of $94.33, signalling upside risk potential of 21.38%. On the other hand HCA Healthcare, Inc. has an analysts' consensus of $481.95 which suggests that it could grow by 1.44%. Given that CVS Health Corp. has higher upside potential than HCA Healthcare, Inc., analysts believe CVS Health Corp. is more attractive than HCA Healthcare, Inc..

CVS Health Corp. has a beta of 0.481, which suggesting that the stock is 51.936% less volatile than S&P 500. In comparison HCA Healthcare, Inc. has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.09%.

CVS Health Corp. has a quarterly dividend of $0.67 per share corresponding to a yield of 3.42%. HCA Healthcare, Inc. offers a yield of 0.61% to investors and pays a quarterly dividend of $0.72 per share. CVS Health Corp. pays 72.76% of its earnings as a dividend. HCA Healthcare, Inc. pays out 12% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health Corp. quarterly revenues are $102.9B, which are larger than HCA Healthcare, Inc. quarterly revenues of $19.2B. CVS Health Corp.'s net income of -$4B is lower than HCA Healthcare, Inc.'s net income of $1.9B. Notably, CVS Health Corp.'s price-to-earnings ratio is 203.14x while HCA Healthcare, Inc.'s PE ratio is 18.28x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health Corp. is 0.25x versus 1.56x for HCA Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Humana, Inc. has a net margin of -3.88% compared to CVS Health Corp.'s net margin of 0.59%. CVS Health Corp.'s return on equity of 0.57% beat Humana, Inc.'s return on equity of 7.3%.

CVS Health Corp. has a consensus price target of $94.33, signalling upside risk potential of 21.38%. On the other hand Humana, Inc. has an analysts' consensus of $287.83 which suggests that it could grow by 10.96%. Given that CVS Health Corp. has higher upside potential than Humana, Inc., analysts believe CVS Health Corp. is more attractive than Humana, Inc..

CVS Health Corp. has a beta of 0.481, which suggesting that the stock is 51.936% less volatile than S&P 500. In comparison Humana, Inc. has a beta of 0.462, suggesting its less volatile than the S&P 500 by 53.84%.

CVS Health Corp. has a quarterly dividend of $0.67 per share corresponding to a yield of 3.42%. Humana, Inc. offers a yield of 1.37% to investors and pays a quarterly dividend of $0.89 per share. CVS Health Corp. pays 72.76% of its earnings as a dividend. Humana, Inc. pays out 35.45% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health Corp. quarterly revenues are $102.9B, which are larger than Humana, Inc. quarterly revenues of $32.6B. CVS Health Corp.'s net income of -$4B is lower than Humana, Inc.'s net income of $194M. Notably, CVS Health Corp.'s price-to-earnings ratio is 203.14x while Humana, Inc.'s PE ratio is 24.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health Corp. is 0.25x versus 0.25x for Humana, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings, Inc. has a net margin of -3.88% compared to CVS Health Corp.'s net margin of 7.34%. CVS Health Corp.'s return on equity of 0.57% beat Labcorp Holdings, Inc.'s return on equity of 10.25%.

CVS Health Corp. has a consensus price target of $94.33, signalling upside risk potential of 21.38%. On the other hand Labcorp Holdings, Inc. has an analysts' consensus of $299.71 which suggests that it could grow by 18.92%. Given that CVS Health Corp. has higher upside potential than Labcorp Holdings, Inc., analysts believe CVS Health Corp. is more attractive than Labcorp Holdings, Inc..

CVS Health Corp. has a beta of 0.481, which suggesting that the stock is 51.936% less volatile than S&P 500. In comparison Labcorp Holdings, Inc. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.121%.

CVS Health Corp. has a quarterly dividend of $0.67 per share corresponding to a yield of 3.42%. Labcorp Holdings, Inc. offers a yield of 1.14% to investors and pays a quarterly dividend of $0.72 per share. CVS Health Corp. pays 72.76% of its earnings as a dividend. Labcorp Holdings, Inc. pays out 32.58% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health Corp. quarterly revenues are $102.9B, which are larger than Labcorp Holdings, Inc. quarterly revenues of $3.6B. CVS Health Corp.'s net income of -$4B is lower than Labcorp Holdings, Inc.'s net income of $261.5M. Notably, CVS Health Corp.'s price-to-earnings ratio is 203.14x while Labcorp Holdings, Inc.'s PE ratio is 24.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health Corp. is 0.25x versus 1.54x for Labcorp Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SCWorx Corp. has a net margin of -3.88% compared to CVS Health Corp.'s net margin of -185.96%. CVS Health Corp.'s return on equity of 0.57% beat SCWorx Corp.'s return on equity of -74.77%.

CVS Health Corp. has a consensus price target of $94.33, signalling upside risk potential of 21.38%. On the other hand SCWorx Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that CVS Health Corp. has higher upside potential than SCWorx Corp., analysts believe CVS Health Corp. is more attractive than SCWorx Corp..

CVS Health Corp. has a beta of 0.481, which suggesting that the stock is 51.936% less volatile than S&P 500. In comparison SCWorx Corp. has a beta of 1.922, suggesting its more volatile than the S&P 500 by 92.248%.

CVS Health Corp. has a quarterly dividend of $0.67 per share corresponding to a yield of 3.42%. SCWorx Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CVS Health Corp. pays 72.76% of its earnings as a dividend. SCWorx Corp. pays out -- of its earnings as a dividend. CVS Health Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CVS Health Corp. quarterly revenues are $102.9B, which are larger than SCWorx Corp. quarterly revenues of $705.8K. CVS Health Corp.'s net income of -$4B is lower than SCWorx Corp.'s net income of -$1.3M. Notably, CVS Health Corp.'s price-to-earnings ratio is 203.14x while SCWorx Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CVS Health Corp. is 0.25x versus 0.32x for SCWorx Corp.. Usually stocks with elevated PS ratios are considered overvalued.